Estonian medtech firm Nanordica Medical has raised €1.75 million to market an innovative antibacterial wound dressing that significantly enhances healing for chronic wounds.

Target Information

Nanordica Medical, an Estonian medtech firm, has successfully raised €1.75 million to launch its innovative wound care products aimed at treating severe wounds. Founded in 2019, the company emerged as a spin-off from the National Institute of Chemical Physics and Biophysics in Estonia. Their flagship wound dressing utilizes a unique combination of copper and silver nanoparticles, significantly enhancing the antibacterial efficacy and promoting improved wound healing.

This advanced dressing is a result of pivotal research conducted by the company's co-founders, evidencing the synergistic effects of these nanoparticles against bacterial infections. With chronic wounds affecting approximately 100 million patients—primarily due to conditions such as diabetes, pressure ulcers, and venous leg ulcers—the need for effective treatments is greater than ever. The ongoing increase in prevalence, rising by 12 percent annually due to an aging global population, exemplifies the urgency of Nanordica Medical's offerings.

Industry Overview in Estonia

The medical technology industry in Estonia has been rapidly evolving, bolstered by a strong ecosystem of research and development stemming from its academic institutions. Estonian universities and research facilit